Objectives
Diabetic nephropathy is a serious and common complication in diabetic patients. However the onset and the course of the diabetic nephropathy can be favourably influenced by appropriate therapy when detected early. In 2004 the independent international Kidney Disease Improving Global Outcome Organisation (KDIGO) recommended 2 laboratory tests for an early detection of chronic kidney disease (CKD): determination of serum creatinine to estimate glomerular filtration rate (eGFR) using the simplified equation derived from the Modification of Diet in Renal Disease Study (MDRD) and determination of proteinuria preferably microalbuminuria corrected for urine creatinine. Creatinine as a marker for eGFR has metabolic and technical limitations, especially in patients with only mild impairment of kidney function. As an alternative marker serum Cystatin C (CysC) has been proposed for early detection of CKD.
We developed a cost-utility-model to simulate the long-term consequences of diabetic nephropathy using CysC instead of creatinine to monitor renal function. Markovmodelling-techniques were used to describe complications and disease progression; one arm assessed the costs and effects of CysC reporting, disease progression and complications, and the other assessed the cost and effect of routine eGFR reporting. Probabilities of complications were derived from clinical and epidemiological studies. The model includes eleven a priori defined health states to describe the disease progression and occurrence of adverse events. Disease progression leads to a passover to the next health state; the others remain. 
Incremental costs

Sensitivity Analysis
Monte Carlo probabilistic sensitivity analysis, results of 1,000 trials plotting incremental cost versus incremental effects, demonstrated that an early detection of CKD with CysC was cost effective compared to creatinine. In more than 99% of the simulations CysC was associated with lower costs and higher effectiveness (plots in the lower right quadrant of Fig. 2 ). The probabilistic as well as the deterministic sensitivity analyses show the robustness of the model.
Conclusion
Our data suggest a substantial economic benefit by using serum cystatin C instead of creatinine for early detection of chronic kidney disease in type 2 diabetes patients in Germany. This is due to a marked reduction in complication and disease progression.
